Format

Send to

Choose Destination
Cell Mol Life Sci. 2010 Jan;67(2):171-7. doi: 10.1007/s00018-009-0189-x. Epub 2009 Nov 12.

Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Author information

1
Discovery Biology, Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way, Jupiter, FL 33458, USA.

Abstract

The emerging critical implications of Rho/Rho-kinase (ROCK) signaling in neurodegenerative diseases, glaucoma, renoprotection, diabetes and cancer have sparked growing interest in the pharmacological potential of ROCK inhibitors beyond their current application in cardiovascular disease. This article discusses the therapeutic benefits of novel ROCK inhibitors in development, and highlights the recent advances in the current understanding of disease-dependent and isoform-specific functions of ROCK and their potential impact on future therapeutic strategies.

PMID:
19907920
DOI:
10.1007/s00018-009-0189-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center